LiBo Pharma Corp.
- Biotech or pharma, therapeutic R&D
- Libo Pharma Corp. – Founded in 2017, focused on unmet medical needs.
- Lead asset: NM-IL-12, a first-in-class cytokine immunotherapy:
- cutaneous T cell Lymphoma (CTCL): EOP2, Phase 3 ready
- Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS): EOP2
- Open Wound Healing: EOP2
- Superior Safety Profile: over 200 subjects dosed, well-tolerated.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}